Debiopharm Group agreed a joint research project with the Ecole Polytechnique Fédérale de Lausanne (EPFL), for the identification of novel small molecules and peptides that interfere with pathways controlling cell fate. The work could lead to the development of novel cancer treatments.
The start of the project follows the signature of the EPFL-Debiopharm partnership on February 12. This first joint research project will be performed under the supervision of Freddy Radtke, Associate Professor at the Swiss Institute for Experimental Cancer Research (ISREC) and Gerardo Turcatti, MER, Director of the Biomolecular Screening Facility (BSF).
The project will draw on molecular and genetic tools generated by Radtke’s group over the past 10 years, and the expertise of Turcatti in the field of molecular screening.
“Targeting pathways controlling cell fate specification could generate innovative anti-cancer drugs with anti-tumoural, anti-metastatic and anti-angiogenic properties to treat tumours that are currently resistant to standard therapies,” said Kamel Besseghir, CEO of Debiopharm
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
